TOGETHER investigated whether targeting multiple cardiovascular (CV) risk factors using
single-pill amlodipine/atorvastatin (AML/ATO) and therapeutic lifestyle changes (TLC) …

Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

Introduction Hypertension and hypercholesterolaemia are important contributors to the
development and progression of atherosclerosis. The coexistence of these two conditions is …

Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …

Background Single-pill amlodipine/atorvastatin targets the two most common modifiable
cardiovascular risk factors, hypertension and dyslipidaemia. We evaluated the clinical utility …

In 2002, the World Health Organization estimated that over 58% of cardiovascular disease in
North America is due to 'both blood pressure and cholesterol higher than optimal' …

Poor control of hypertension or dyslipidemia may at least in part be due to these risk factors
being treated in isolation. The Caduet in Untreated Subjects Population (CUSP) trial was an …

BACKGROUND: We hypothesized that atorvastatin combined with amlodipine has additive
beneficial vascular and metabolic effects that are superior to monotherapy in patients with …

Purpose A fixed-dose combination of a stain and an antihypertensive drug may be useful for
the treatment of patients with hypertension and hyperlipidemia. It may also improve patient …

Background: Community-based studies are conducted to determine the degree to which
therapeutic interventions will succeed in real world settings. This large practice-based …